$Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05$

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Purpose Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear. Methods We investigated 1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2021-08, Vol.147 (8), p.2459-2469
Hauptverfasser:	Park, Ji Hyun, You, Gun Lyung, Ahn, Myung-Ju, Kim, Sang-We, Hong, Min Hee, Han, Ji-Youn, Ock, Chan-Young, Lee, Jong-Seok, Oh, In Jae, Lee, Shin Yup, Kim, Cheol Hyeon, Min, Young Joo, Choi, Yoon Hee, Ryu, Jeong-Seon, Park, Sun Hyo, Ahn, Hee Kyung, Shim, Byoung-Yong, Lee, Ki Hyeong, Lee, Sung Yong, Kim, Jin-Soo, Yi, Jiun, Choi, Su Kyung, An, Hyonggin, Kang, Jin Hyoung
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adverse events Antibodies Apoptosis Cancer Research Chemotherapy Clinical trials Epidermal growth factor receptors Hematology Immune checkpoint inhibitors Internal Medicine Lung cancer Medicine Medicine & Public Health Metastases Metastasis Mutation Non-small cell lung carcinoma Oncology Original Article – Clinical Oncology Patients PD-1 protein PD-L1 protein Pembrolizumab Platinum Small cell lung carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!